Michelle Kramer

2.6k total citations
27 papers, 1.9k citations indexed

About

Michelle Kramer is a scholar working on Psychiatry and Mental health, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Michelle Kramer has authored 27 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Psychiatry and Mental health, 7 papers in Pharmacology and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Michelle Kramer's work include Schizophrenia research and treatment (21 papers), Bipolar Disorder and Treatment (11 papers) and Epilepsy research and treatment (6 papers). Michelle Kramer is often cited by papers focused on Schizophrenia research and treatment (21 papers), Bipolar Disorder and Treatment (11 papers) and Epilepsy research and treatment (6 papers). Michelle Kramer collaborates with scholars based in United States, Belgium and New Zealand. Michelle Kramer's co-authors include Mariëlle Eerdekens, Pilar Lim, Fred Grossman, Lisa Ford, Rosanne Lane, Keith Karcher, David Hough, Sumant Khanna, Cristiana Gassmann-Mayer and Robin Emsley and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and The British Journal of Psychiatry.

In The Last Decade

Michelle Kramer

27 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michelle Kramer United States 15 1.6k 283 254 181 172 27 1.9k
Dan Zimbroff United States 12 890 0.5× 266 0.9× 317 1.2× 125 0.7× 117 0.7× 21 1.3k
P. Tran United States 10 1.2k 0.8× 453 1.6× 292 1.1× 266 1.5× 94 0.5× 22 1.9k
Lisa A. Arvanitis United States 14 1.4k 0.9× 377 1.3× 283 1.1× 222 1.2× 124 0.7× 34 1.8k
György Németh Hungary 25 1.6k 1.0× 460 1.6× 280 1.1× 120 0.7× 84 0.5× 86 2.1k
J. Street United States 10 1.4k 0.8× 354 1.3× 278 1.1× 210 1.2× 76 0.4× 29 1.6k
Pierre V. Trân United States 17 1.5k 0.9× 616 2.2× 297 1.2× 304 1.7× 74 0.4× 28 1.9k
Spyridon Siafis Germany 22 985 0.6× 250 0.9× 258 1.0× 184 1.0× 82 0.5× 79 1.6k
Heike Hunger Germany 13 1.5k 0.9× 273 1.0× 282 1.1× 245 1.4× 98 0.6× 14 1.9k
Mirza W. Ali United States 16 2.0k 1.2× 396 1.4× 283 1.1× 292 1.6× 252 1.5× 30 2.6k
Ibrahim Turkoz United States 22 1.3k 0.8× 566 2.0× 411 1.6× 199 1.1× 71 0.4× 98 1.8k

Countries citing papers authored by Michelle Kramer

Since Specialization
Citations

This map shows the geographic impact of Michelle Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Kramer more than expected).

Fields of papers citing papers by Michelle Kramer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Kramer. The network helps show where Michelle Kramer may publish in the future.

Co-authorship network of co-authors of Michelle Kramer

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Kramer. A scholar is included among the top collaborators of Michelle Kramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Kramer. Michelle Kramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Starr, H. Lynn, Sandy Lewis, Carla DeMuro, et al.. (2020). Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study. Psychiatry Research. 293. 113376–113376. 9 indexed citations
2.
Kramer, Michelle, et al.. (2017). Additive Manufacturing of Catalyst Substrates for Steam–Methane Reforming. Journal of Materials Engineering and Performance. 27(1). 21–31. 13 indexed citations
3.
Hough, David, et al.. (2010). Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals. International Clinical Psychopharmacology. 26(1). 25–34. 27 indexed citations
4.
Kramer, Michelle, George M. Simpson, Valentinas Mačiulis, et al.. (2010). One-Year Open-Label Safety and Efficacy Study of Paliperidone Extended-Release Tablets in Patients With Schizophrenia. CNS Spectrums. 15(8). 506–514. 11 indexed citations
5.
Kramer, Michelle, Robert E. Litman, David Hough, et al.. (2009). Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. The International Journal of Neuropsychopharmacology. 13(5). 635–647. 140 indexed citations
6.
Meltzer, Herbert Y., William V. Bobo, Rosanne Lane, et al.. (2008). Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia. The Journal of Clinical Psychiatry. 69(5). 817–829. 130 indexed citations
7.
Emsley, Robin, Joris Berwaerts, Mariëlle Eerdekens, et al.. (2008). Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. International Clinical Psychopharmacology. 23(6). 343–356. 69 indexed citations
8.
Kramer, Michelle, George M. Simpson, Valentinas Mačiulis, et al.. (2007). Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia. Journal of Clinical Psychopharmacology. 27(1). 6–14. 169 indexed citations
9.
10.
Davidson, Michael, Robin Emsley, Michelle Kramer, et al.. (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophrenia Research. 93(1-3). 117–130. 203 indexed citations
11.
Marder, Stephen R., Michelle Kramer, Lisa Ford, et al.. (2007). Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study. Biological Psychiatry. 62(12). 1363–1370. 177 indexed citations
12.
13.
Kane, John M., F. Cañas, Michelle Kramer, et al.. (2006). Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial☆. Schizophrenia Research. 90(1-3). 147–161. 229 indexed citations
14.
Kramer, Michelle, Isaac Nuamah, Pilar Lim, & Mariëlle Eerdekens. (2006). P.3.a.039 Onset of action of oral paliperidone extended-release tablets in patients with acute schizophrenia: pooled results from three 6-week controlled studies. European Neuropsychopharmacology. 16. S385–S386. 2 indexed citations
15.
Gopal, Srihari, David C. Steffens, Michelle Kramer, & Catherine M. Olsen. (2005). Symptomatic Remission in Patients With Bipolar Mania. The Journal of Clinical Psychiatry. 66(8). 1016–1020. 34 indexed citations
16.
Khanna, Sumant, Eduard Vieta, Benjamin Lyons, et al.. (2005). Risperidone in the treatment of acute mania. The British Journal of Psychiatry. 187(3). 229–234. 131 indexed citations
17.
Hirschfeld, Robert M. A., Paul E. Keck, Michelle Kramer, et al.. (2004). Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial. American Journal of Psychiatry. 161(6). 1057–1065. 177 indexed citations
18.
Ab, Smulevich, Sumant Khanna, Mariëlle Eerdekens, et al.. (2004). Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. European Neuropsychopharmacology. 15(1). 75–84. 120 indexed citations
19.
Kramer, Michelle, et al.. (2002). Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology. 16(4). 365–368. 82 indexed citations
20.
Kramer, Michelle, et al.. (2001). Consumers Who Call the Anxiety Disorders Association of America: Characteristics and Satisfaction. The Journal of Nervous and Mental Disease. 189(5). 328–331. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dan Zimbroff Breakdown of academic impact, for papers by P. Tran Breakdown of academic impact, for papers by Lisa A. Arvanitis Breakdown of academic impact, for papers by György Németh Breakdown of academic impact, for papers by J. Street Breakdown of academic impact, for papers by Pierre V. Trân Breakdown of academic impact, for papers by Spyridon Siafis Breakdown of academic impact, for papers by Heike Hunger Breakdown of academic impact, for papers by Mirza W. Ali Breakdown of academic impact, for papers by Ibrahim Turkoz
Rankless by CCL
2026